European Commission Approves Merck’s KEYTRUDA® Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer (NSCLC) at ...
Merck announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small …